About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Posttraumatic Stress Disorder
Long Covid
Cocaine Intoxication
Migraine
Depression
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
COVID-19
Monkeypox
Smallpox
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-601 ER
TNX-1300
TNX-1900
TNX-4300
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-1850
TNX-801
Rare Disease
TNX-2900
Scientific Presentations
Expanded Access Policy
Medicines
Clinical Trials
News & Events
Tonix in the News
Press Releases
Investor Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
Presentations
Investors
Investors
Overview
News & Events
Tonix in the News
Press Releases
IR Events
Email Alerts
Op-Eds
Presentations
Multimedia
Financial Info
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
Summary Investor Presentation
Sep 19, 2023
Investor Presentation September 2023
Program-Specific Presentations
Sep 19, 2023
TNX-102 SL for Fibromyalgia and Long COVID
Sep 11, 2023
TNX-1300 for Cocaine Intoxication
Aug 16, 2023
TNX-1500 for Organ Transplant Rejection & Autoimmune Disorders
Aug 1, 2023
TNX-1900 for Chronic Migraine
Aug 1, 2023
TNX-601 ER and TNX-4300 for Major Depressive Disorder
Jul 13, 2023
TNX-801 for Smallpox and Monkeypox
Jun 13, 2023
TNX-1700 for Gastric and Colorectal Cancers
May 8, 2023
TNX-1500 for Organ Transplant Rejection & Autoimmune Disorders
Jul 19, 2022
TNX-2900 for Prader-Willi Syndrome
Factsheet
Sep 11, 2023
Tonix Factsheet
Conference Materials
Jul 11, 2022
World Orphan Drug Congress 2022
rss_feed
RSS
